Quince Therapeutics shares jump 16.82% intraday after announcing investor events and Phase 3 NEAT trial updates.

Quince Therapeutics surged 16.82% intraday following announcements of high-profile investor engagements and Phase 3 clinical trial progress. The company’s management will participate in three December 2025 events, including a Piper Sandler Healthcare Conference fireside chat and an Oppenheimer panel highlighting rare disease companies with near-term catalysts, such as Quince’s pivotal NEAT trial topline results expected in Q1 2026. Additionally, a strategic partnership with Option Care Health to commercialize its eDSP therapy was cited as a key driver, bolstering confidence in its rare disease pipeline. These developments—underscoring clinical milestones, commercial readiness, and investor visibility—aligned.